Author:
Zhang Zhihao,Zhou Jinhu,Ni Peng,Hu Bing,Deng Shuang,Xiao Qian,He Qian,Li Gai,Xia Yan,Liu Mei,Wang Cong,Fang Zhizheng,Xia Nan,Zhang Zhe-Rui,Zhang Bo,Cai Kun,Jolicoeur Normand,Xu Yan,Liu Binlei
Abstract
AbstractThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has had and still has a considerable impact on global public health. One of the characteristics of SARS-CoV-2 is a surface homotrimeric spike protein, the primary responsible for the host immune response upon infection. Here we show the preclinical studies of a broad protective SARS-CoV-2 subunit vaccine developed from our Trimer Domain platform using the Delta spike protein, from antigen design to purification, vaccine evaluation and manufacturability. The prefusion trimerized Delta spike protein, PF-D-Trimer, was highly expressed in Chinese hamster ovary (CHO) cells, purified by a rapid one-step anti-Trimer Domain monoclonal antibody immunoaffinity process and prepared as a vaccine formulation with an adjuvant. The immunogenicity studies demonstrated that this vaccine candidate induces robust immune responses in mouse, rat and Syrian hamster models. It also protects K18-hACE2 transgenic mice in a homologous virus challenge. The neutralizing antibodies induced by this vaccine display a cross-reactive capacity against the ancestral WA1 and Delta variants as well as different Omicron, including BA.5.2. The Trimer Domain platform was proven to be a key technology in the rapid production of the PF-D-Trimer vaccine and may be crucial to accelerate the development of updated versions of SARS-CoV-2 vaccines.
Publisher
Cold Spring Harbor Laboratory
Reference45 articles.
1. WHO. WHO Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update, < https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> (2022).
2. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 7798 (2020).
3. Wrapp, D. , Wang, N. , Corbett, K. S. , Goldsmith, J. A. & Mclellan, J. S. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science 1260– 1263 (2020).
4. A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development;Pathogens,2021
5. Viral targets for vaccines against COVID-19